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ABSTRACT: Preventing the spread of infectious diseases remains an
urgent priority worldwide, and this is driving the development of
advanced nanotechnology to diagnose infections at the point of care.
Herein, we report the creation of a library of novel nanobody capture
ligands to detect p24, one of the earliest markers of HIV infection. We
demonstrate that these nanobodies, one tenth the size of conventional
antibodies, exhibit high sensitivity and broad speciﬁcity to global HIV-
1 subtypes. Biophysical characterization indicates strong 690 pM
binding constants and fast kinetic on-rates, 1 to 2 orders of magnitude
better than monoclonal antibody comparators. A crystal structure of
the lead nanobody and p24 was obtained and used alongside
molecular dynamics simulations to elucidate the molecular basis of these enhanced performance characteristics. They indicate
that binding occurs at C-terminal helices 10 and 11 of p24, a negatively charged region of p24 complemented by the positive
surface of the nanobody binding interface involving CDR1, CDR2, and CDR3 loops. Our ﬁndings have broad implications on
the design of novel antibodies and a wide range of advanced biomedical applications.
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HIV is one of the fastest evolving of all organisms,presenting a challenge to the development of vaccines
and diagnostics. Selection of a stable and consistent antigenic
target is diﬃcult due to the rapid rate of evolution, which is a
combined eﬀect of the high mutation rate and a recombination
rate that is at the limit known for any organism.1 HIV-1
currently infects 34 million people worldwide, with high
morbidity and mortality in Sub-Saharan Africa.2 However, even
in the UK, more than one in ﬁve people are unaware of their
infection, and 47% of diagnoses are at a late stage of AIDS.3
Early diagnosis plays a crucial role in all treatment and
prevention strategies. It enables individual patients to gain
faster access to care and treatment.4 In turn, this protects the
wider public from the risk of subsequent infection, leading to
major human and economic beneﬁts to society.5,6 This has led
to broad policy changes to widen access to care outside of
centralized hospitals, including doctor’s surgeries, pharmacies,
community outreach settings, and the home, including self-
testing, which is now legal in several countries including the US
and UK.7,8
The p24 capsid protein is the earliest protein biomarker of an
HIV-1 infection and used in gold-standard HIV-1 fourth
generation diagnostic tests. However, p24 detection is not
widely used in point of care (POC) tests, which typically rely
on just antibody detection, meaning that recent infections pass
undetected before seroconversion, which can take 3−6
months.9 The ﬁrst fourth generation POC test (detecting p24
and anti-HIV antibodies) to be approved has shown variable
results for p24 detection in the ﬁeld.10 The reasons behind this
failure are unclear, but POC testing in resource-limited settings
poses particular challenges, with little sophisticated laboratory
instrumentation, no inbuilt immune complex disruption to
dissociate p24 from complexing host antibodies, and no cold
chain transportation to maintain reagent stability.11 This
highlights the need for more sensitive, speciﬁc, and robust
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Figure 1. Schematics to show the structure of HIV, antibodies, and nanobodies, the method of generation of our p24 nanobodies, and
characterization of thermodynamic and kinetic binding measurements for nanobodies and mAb comparators. (a) Schematic of a virion of HIV
highlighting key antigens; (b) Schematic to compare the structures of a conventional mAb, heavy chain only antibody, and a nanobody with
indicated domain substructure. CH, constant heavy; VH, variable heavy; CL, constant light; VL, variable light; VHH, variable domain of a heavy
chain-only antibody; (c) Outline of the phage library construction, screening, and nanobody selection after inoculation of a llama with target antigen,
p24 (this process is described in more detail in ref 32); (d) Plots to show the comparison of binding of diﬀerent p24 subtypes by four nanobodies
and two p24-binding mAbs. Shown are the results from an indirect ELISA for subtype B (EVA620), subtype C (ARP695), subtype C (92BR025),
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sensor technologies that can detect p24 in POC tests suitable
for all settings.
Monoclonal antibodies (mAbs) have been the bedrock of
many diagnostics for decades, and the diversity of the antibody
repertoire generated by immunization of animals is unmatched;
yet, the process yields a molecule with a largely unknown
sequence and structure, batch to batch variation,12 that is
sensitive to denaturation,13 is insuﬃciently pliable, and is often
simply too large for today’s nano and quantum diagnostic
technologies, for example, Förster resonance energy transfer
quantum dot biosensors (1 to 10 nm).14,15 Future advances in
diagnostics depend on ground-breaking technological develop-
ments occurring at the interface of biology, nanoscale physics,
chemistry, and engineering, with the creation of novel sensing
tools and systems that permit the detection of ultralow levels of
biomarkers.16
Nanobodies, which are recombinant antigen-binding do-
mains from camelid antibodies, oﬀer a number of signiﬁcant
advantages over conventional monoclonal and polyclonal
antibodies. Conventional mammalian antibodies are composed
of variable heavy and light chains, and diversity is generated by
recombination and hypermutation. The llama antibody
repertoire comprises approximately 70% conventional antibod-
ies with 30% heavy-chain only antibody but still possesses a
comprehensive repertoire.17−19 The physical properties and
characteristics of the variable domains of these heavy chain-only
antibodies (VHH) have been studied in terms of their physical
properties, and characteristics include resistance to inactivation
by heat or low pH, binding in the presence of inhibitors, and
high potency and speciﬁcity.20−24 The VHH can be cloned into
vectors and produced in E. coli and yeast; thus, these are highly
manipulable and scalable to produce large quantities.25
Nanobodies are around a tenth the size of a conventional
antibody at 11−15 kDa, permitting them access to clefts and
regions of the target protein for which a conventional antibody
would be too big.14,26 To date, applications for nanobodies
developed and reported have included imaging, therapeutic
applications, and targeted inhibitors of enzymes or neutralizing
antibodies, among others,23,27−30 and potential future applica-
tions have been recently reviewed.31
Maximizing the sensitivity of diagnostic tests involves
overcoming research challenges such as elucidating how each
constituent interacts with its partners, from biological sensor
components to the signal measured by the sensor device. The
characteristics of nanobodies facilitate these analyses as their
sequence can be easily determined due to the formation of the
antigen-binding site by a single polypeptide chain. Additionally,
less computational processing power is required for modeling
of tertiary structure and interactions with binding partners
compared to larger molecules such as mAbs.
Herein, we report the development of novel nanobodies to
detect HIV-1 p24. Lead candidates were selected on the basis of
aﬃnity, and their binding properties to diﬀerent p24 subtypes
were investigated, including those against a 50-member panel
representing major circulating strains of HIV-1. The biophysical
thermodynamics and kinetics of nanobody−p24 interactions
were then studied by protein interaction detection methods and
compared to those of two mAbs. We were able to obtain a
crystal structure at 2.8 Å of a high-aﬃnity nanobody bound to
p24. Despite near-identical primary amino acid sequences, two
of the nanobodies had very diﬀerent binding properties, and
therefore, we used molecular dynamics simulations to unravel
the underpinning contribution of electrostatics and hydro-
phobic forces. We believe this is the ﬁrst published study to
report the characterization of HIV-1 anti-p24 nanobodies that
have potential for use as capture tools in fourth generation
HIV-1 diagnostics. Here, we focus on HIV-1 because of the
enormous unmet clinical need for better diagnostics, but the
principles of our work can also be applied to a broad range of
other disease areas.
■ RESULTS AND DISCUSSION
Immunization of two llamas (Lama glama) with HIV-1 p24
(subtypes B/C) (Figure 1a) generated a panel of nanobodies
against p24 (Figure 1b,c). From the panel, ﬁve nanobodies
were identiﬁed by aﬃnity screening as lead candidates, of which
three (37E7, 59H4, and 59H10) were taken for further
investigation. They were initially assessed for their ability to
detect a broad range of p24 subtypes by an indirect enzyme-
linked immunosorbent assay (ELISA) with seven puriﬁed
recombinant p24 subtypes (HIV-1 Group M subtypes B, C, C,
D, CRF01_AE, and Groups N and O, Figure 1d).
The results are summarized in Figure 1d and Table S1. Two
comparator mAbs were evaluated in parallel, CP-HIV-1/2 (a
commercial antibody, green line) and NIH-3537 from the
AIDS Reagent Program (red line).34 The ELISA data (Figure
1d) and derived aﬃnity constants (Table S1) highlight that the
nanobody 59H10 (blue line) is able to bind to all subtypes with
0.2- to 17-fold aﬃnity compared to the best comparator mAb
tested. A control nanobody to Bacteriophage p2 ORF18
protein, LAB533 (black line), was also included and showed no
binding.
The ability of 59H10 to detect a much larger range of HIV-1
subtypes was tested next, as the number of p24 variants
Figure 1. continued
subtype D (NDK), and subtype AE (CM240), representative of Group N (06CM-U14296) and representative of Group O (BCF06) with
nanobodies 59H10, 37E7, 59H4 and LAB5, and mAbs NIH-3537 and Capricorn HIV-1/2 (CP-HIV-1/2). LAB5 is a control nanobody that was
raised to a phage protein.33 Shown is the molarity of antibody or nanobody versus the OD achieved (at 450 nm). Results are combined from at least
two experiments. (e) A sandwich ELISA was performed to assess detection of 50 viral strains from the EQAPOL viral subtype diversity panel. The
ELISA was in a sandwich format with a mAb capture antibody (CP-HIV-1/2) and 59H10 detection nanobody. Error bars show standard deviation of
the mean from at least 6 wells across 2 or 3 independent experiments. (f) (i−v) Plots showing the relative wavelength shift against time measured by
biolayer interferometry of sensors coated with p24 to seven diﬀerent concentrations of each analyte for (i) 59H10; (ii) 48G11 (raw data shown
instead of relative binding as raw data showed no binding; therefore, data could not be normalized as other analytes); (iii) 37E7 nanobody; (iv) CP-
HIV-1/2; (v) NIH-3537. (g) Summary plot to compare the binding aﬃnities of 59H10 (blue circles), CP-HIV-1/2 (red squares), NIH-3537 (green
diamonds), and 37E7 (orange triangles). The log−linear plot shows the fractional saturation signal as a function of analyte concentration and the ﬁts
correspond to the Langmuir Adsorption Isotherm model. (h) A plot comparing the measured observed rate constants, kobs, for 59H10 (blue circles)
and CP-HIV-1/2 (red squares) as a function of the analyte concentration. The linear regression ﬁt shown was used to determine the kinetic on-rate
constant kon (slope) and oﬀ-rate constant koff (intercept) where R
2 = 0.99955 for 59H10 and R2 = 0.99193 for CP-HIV-1/2. A summary of the
thermodynamic and kinetic parameters of nanobodies and mAbs is given in Table 1.
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available as recombinant proteins is limited. The Viral Diversity
Program panel (EQAPOL, Duke University, USA) contains a
selection of 50 viral strains that reﬂects the diversity of strains
found worldwide, spanning most common strains to rare
isolates and unusual recombinants.35 A sandwich ELISA was
created with 59H10 and CP-HIV-1/2, and results in Figure 1e
show that 59H10 has consistently strong levels of binding with
48/50 members of this panel. This indicates binding across all
the strains tested irrespective of the intersubtype sequence
diﬀerences, including subtype C, which is currently the source
of most infections worldwide, with 5 representatives within the
EQAPOL panel.36,37 One notable exception was subtype D,
where variable levels of nanobody sensitivity were observed
(Figure S1). These ﬁndings are in agreement with other studies
involving subtype D strains.38 Nevertheless, these results
highlight that 59H10 shows excellent binding to all the major
circulating strains of HIV worldwide.
The ELISA studies provided an initial semiquantitative
screen of lead nanobodies candidates; however, a potential
limitation is that diﬀerent labeling protocols were necessary for
nanobodies and mAbs, which could potentially inﬂuence the
binding constants. Therefore, to better understand the
biophysical performance characteristics of the nanobodies, the
thermodynamics and kinetics of binding to p24 were studied
using the label-free method of biolayer interferometry which
requires no sample labeling of the nanobodies or mAbs and
instead relies on optical detection of interference patterns when
binding occurs to p24 coated probes over time. Additionally, a
new nanobody mutant was created from 59H10, dubbed
48G11, in which a single F93D mutation in the CDR3 loop was
made to change the charge environment of this region. Initial
biolayer interferometry binding studies showed that this single
change in 48G11 abolished all binding to p24 (Figure S2). A
summary of parameters obtained from the biolayer interfer-
ometry data is shown in Table 1 and the raw data in Figure 1f.
The processing methodology for the data is shown in Figure
S3. Of all the mAbs and nanobodies tested, 59H10 showed the
fastest kinetic-on rates (kon, 3.5 × 10
5 M−1 s−1) and was found
to be 10- to 100-fold faster than mAb comparators. 59H10 also
showed the strongest thermodynamic equilibrium dissociation
binding constant of all ligands tested, at a KD of 6.9 × 10
−10 M
making it by deﬁnition a high aﬃnity antibody (where KD < 1 ×
10−9 M). The corresponding calculated Gibbs free energy, ΔG,
is −54.4 kJ/mol, where ΔGexpt= −RT ln(1/KD). By comparison,
measured dissociation constants for mAbs were found to be
between 2.3- to over 10-fold weaker. Both nanobodies and
mAbs showed good agreement with a 1:1 Langmuir adsorption
isotherm model, although it cannot be ruled out that mAbs
could interact bivalently, particularly at high loading densities of
p24.
In order to probe the molecular basis for the binding of the
nanobodies to p24, the two lead nanobodies (59H10 and
37E7) and the artiﬁcial mutant 48G11 were further
characterized. Sequencing of 37E7 and 59H10 revealed high
levels of amino acid identity (111/114), diﬀering only in 3
amino acids, (F55G, D56Y, and P57A, Kabat numbering39) in
the complementarity determining region (CDR) loop 2 (Table
2). This is intriguing considering that their binding aﬃnity to
p24 diﬀers by orders of magnitude and complies with
observations that in nanobodies all three hypervariable regions
(CDR1, -2, and -3) are involved in antigen binding (Figure
1d,e, Table 1, and refs 40−42). To ascertain the eﬀects of these
substitutions on the tertiary structure of the nanobodies, the
p24−59H10 nanobody complex was crystallized and its
structure solved by molecular replacement (Figure 2 and
Table 3).
While solving the structure, it became apparent that the N-
terminal domain was missing in the crystal, probably due to
proteolysis in the crystallization drop. The crystal structure
reveals that the nanobody 59H10 employs its β-sheet and
CDR1, -2, and -3 to interact with the C-terminal domain of p24
in contact with the 2 C-terminal α-helices 10 and 11 (Figure
2a,b). The interaction is stabilized by one salt bridge between
59H10 R50 and p24 E213 and four hydrogen bonds (Figure
2c). 59H10 N32 OD1 hydrogen bonds to p24 Q219 NE2, W37
NE1 to the carbonyl of p24 A204, and 59H10 R50 NH1 to the
carbonyls of p24 L205 and P207. Additional hydrophobic
contacts involve W37, F47, F93, A95, L96, and A101 of 59H10
Table 1. Summary of the Thermodynamic Equilibrium Dissociation Constant Values, KD (M), Kinetic On-Rate, kon (M
−1 s−1),
Kinetic Oﬀ-Rate, koff (s
−1), As Measured by Biolayer Interferometry, and the Corresponding Calculated Gibbs Free Energies,
ΔGexpt (kJ/mol), for Diﬀerent Nanobodies and mAbs Binding to p24 (where ΔGexpt= −RT ln(1/KD))a
nanobody mAb
biophysical parameters 59H10 37E7 NIH-3537 CP HIV-1/2
KD (M) 6.9 (3.9−9.8) × 10−10 1.1 (0.9−1.4) × 10−7 2.2 (1.5−2.5) × 10−8 1.6 (1.1−2.0) × 10−9
kon (M
−1s−1) 3.7 (3.6−3.8) × 105 4.2 (3.0−5.4) × 104 2.1 (1.6−2.7) × 103 4.5 (3.7−5.4) × 104
koff (s
−1) 2.9 (1.9−3.9) × 10−4 6.4 (2.3−10.5) × 10−3 1.7 (1.5−1.9) × 10−4 2.0 (1.0−2.9) × 10−4
ΔGexpt (kJ/mol) −54.4 (−55.8/−53.5) −41.3 (−41.8/−40.7) −47.0 (−46.4/−45.1) −52.2 (−53.2/−51.6)
aEach biophysical parameter is shown with the corresponding 95% conﬁdence interval indicated in brackets. The KD was determined from ﬁts of the
experimental data, shown in Figure 1f, using the Langmuir Adsorption isotherm (1:1). The kon and koff were determined from the observed reaction
rate, kobs (Figure S3). All assays were carried out using HIV-1 subtype B p24 (AG6054). mAb = monoclonal antibody.
Table 2. Comparison of Variations in Amino Acid Sequence
in the CDR2 and CDR3 for Diﬀerent Nanobodiesa
variance in amino acid
sequence
nanobody
name
relative thermodynamic binding
aﬃnity
CDR2
loop
CDR3
loop
59H10 high FDP F
48G11 none FDP D
37E7 intermediate GYA F
aShown are the substituted variations between each nanobody only.
59H10 exhibits the “best” binding to p24, 48G11 has no binding, and
37E7 has an intermediate level. Sequence comparison is shown for the
variant CDR2 and CDR3 loops only; the rest of the structure
including CDR1 and loop 4 regions are identical for all three
nanobodies. 48G11 was generated by site-directed mutagenesis to the
CDR3 loop. 37E7 is a CDR2-loop variant identiﬁed from the original
repertoire library.
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to p24 A204 and L205, the closest of these contacts to the
59H10 R50 and p24 E213 salt bridge. The HIV-1 capsid
protein p24 exists in diﬀerent oligomeric forms including
dimers, pentamers, and hexamers.43 In principle, the nanobody
59H10 can potentially bind all forms (PDB code 5HGN),44
(PDB code 5I4T),45 (PDB code 2M8L)46) due to the exposure
of the binding epitope. Interaction with p24 present in the
mature capsid47 would not be expected because the nanobody
binding epitope is partly occluded in the polymeric form.
To validate the p24 epitope for 59H10, recombinant p24
with a truncation after L189 (cleaving helix 9) was used in an
indirect ELISA, and the results were compared to a full p24. A
range of conventional mAbs was used that had previously had
their epitopes mapped, in addition to polyclonal antibodies.
Figure S4 shows that while antibodies mapped to bind between
helices 1 and 8 showed equivalent binding to full or truncated
p24, 59H10 showed no binding to the truncated form of p24.
This provides strongly supportive functional data for the
epitope of p24 shown by the crystal data in Figure 2.
To unravel the molecular basis of the diﬀerences in aﬃnity
between the nanobodies and p24, caused by the single (48G11)
or triple mutations (37E7) in the CDR3 or CDR2 loops,
respectively, three-dimensional conformations of the selected
nanobodies and their interactions with p24 were next
investigated using molecular dynamics simulations. First, to
ensure in silico models were created to be compatible with the
crystal structure of 59H10 (Figure 2) and to probe the
individual tertiary structures of the nanobodies individually,
structural models were created by homology. These were
referenced to the published nanobody D7 (PDB 2XA3), which
has associated literature,40 to facilitate comparison to previous
studies. D7 is a nanobody which binds to a diﬀerent HIV
antigen, the envelope protein gp120, and has a long, ﬂexible
CDR3 loop of 18 amino acids.40 To create starting structures
for relaxation, the input for nanobody atomic coordinates was
derived from structure homology using Swissprot.48 To obtain
equilibrated and stable nanobody geometries, molecular
dynamics simulations were run for 100 ns using an NVT
ensemble at 333 K. Figure 3a shows the crystal structure of
PDB entry 2XA3, for nanobody D7, shown here for
comparison to the p24 binding nanobodies. The mode of
interaction for D7 binding is thought to be via the long CDR3
loop. The long CDR3 is found in another gp120-binding
nanobody, A12 (PDB 3RJQ), and is thought to mediate a
favorable inserted conﬁguration into the pocket of gp120.40 Its
absence in the p24-binding nanobodies suggests that they could
bind by a completely diﬀerent mechanism.
Comparisons of structure and sequence are shown in the
view of superimposed 59H10, 48G11, and 37E7 and colored by
sequence homology in Figure 3b and structural homology in
Figure 3c. Figure 3b highlights the extensive (blue) homology
with two regions of divergence. A comparison of Figure 3b,c
shows that the sequence and structural diﬀerences do not
exactly overlay. The structures of the nanobodies typically
comprise an antiparallel barrel shape of 9 β-strands connected
by loops that make 2 β-sheets. The exception is 37E7, which
shows an α-helix turn in the CDR1. This CDR1 α-helix turn
appears to be a secondary eﬀect of changes in the CDR2 loop
between 59H10 and 37E7. Figure 3d−f shows the equilibrated
Figure 2. X-ray crystal structure of the epitope−paratope binding
regions of p24 C-terminal domain in complex with the nanobody
59H10. (a) Sequence of the nanobody 59H10 and HIV capsid p24
present in the crystal structure. The diﬀerent CDRs of the nanobody
are highlighted, CDR1 (purple), CDR2 (red), and CDR3 (dark blue)
along with 59H10 W37 (green) which is an unusual maturation
mutation. The alpha helices H10 and H11 of p24, involved in the
interaction with 59H10 nanobody, are highlighted in yellow. (b)
Ribbon diagram of the paratope of 59H10 (light blue), a large
interface involving CDR1, -2, and -3, and the epitope of p24 (yellow),
involving helices 10 and 11. 59H10 interacts with p24 helices 10 and
11. The diﬀerent CDRs of the 59H10 are colored as described in (a).
(c, d) Close up of the interactions. (c) salt bridges (59H10 R50 and
p24 E213) and hydrogen bonds (59H10 W37 to p24 A204; 59H10
N32 to p24 Q219; 59H10 R50 to p24 P207 and L205) between
interacting residues are indicated as dashed lines. (d) Visualization of
the hydrophobic contacts around the 59H10 R50 to p24 E213
interaction, rendered in van der Waals and colored gray.
Table 3. Crystallographic Data and Reﬁnement Statisticsa
p24−59H10
data collection
space group P1211
cell dimensions
a, b, c (Å) 40.993, 72.228, 69.953
α, β, γ (deg) 90, 91.398, 90
wavelength 0.976251
resolution (Å) 36.11−2.76 (2.91−2.76)a
Rmerge 0.147 (0.712)
I/σI 6.1 (1.7)
completeness (%) 98 (98.5)
multiplicity 3.0 (3.0)
reﬁnement
resolution (Å) 2.76
no. reﬂections 10360
Rwork/Rfree 0.2211/0.2535
no. atoms
protein 2898
ligand/ion 0
water 0
B-factors
protein 43.01
ligand/ion
water
RMS deviations
bond lengths (Å) 0.003
bond angles (deg) 0.58
PDB code 5O2U
aData from 1 crystal was used for the structure determination.
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molecular dynamics simulated structures of 59H10 (d), 48G11
(e), and 37E7 (f) separately to highlight the variant amino
acids, drawn in ball-and-stick and circled in red. A comparison
of the structure of 59H10 derived from the crystal (Figure 2)
and from molecular dynamics atomistic simulations modeling
59H10 under experimental conditions used for the crystal-
lization show that the root-mean-square deviation (RMSD) of
the crystal and molecular dynamics structure after relaxation
and equilibration is small, at 1.29 Å (Figure S5). The RMSDs of
all molecular dynamics structures (including 48G11 and 37E7)
with time are shown in Figure S6. These show that, after
relaxation and equilibration, structures do not deviate far from
initial postequilibration coordinates. There is no upward drift
shown over time, which indicates structural stability and that
the models are suitable for aiding understanding of the
diﬀerences in structure between the nanobodies.
The crystal structure of 59H10 and p24 was used as a basis
for molecular dynamics simulations of binding between 59H10,
48G11, or 37E7 and p24. This was done to probe the binding
interaction in depth in bioassay conditions and to investigate
the relative diﬀerences between the three nanobodies. The
energetic contributions of individual residues were calculated,
and models showing the importance of the residues at the
interfaces are shown in Figure 4. The ﬁgures here show key
amino acids colored red for favorable or blue for unfavorable
contributions to binding. These total contributions are found
from a Molecular Mechanics Poisson-Boltzmann Surface Area
(MMPBSA) method and sum the electrostatic and van der
Waals contributions (from the molecular dynamics) and the
polar and apolar contributions (from the solution of the
Poisson-Boltzmann equation and surface tension analysis,
respectively). From this analysis and a comparison of the
three nanobodies, it appears that the 59H10 R50 and p24 E213
salt bridge is an important and very favorable interaction.
Figure S7 shows scatter plots for the numeric breakdown of
the energetic contributions as visualized in Figure 4,
individually for the nanobody and p24. The contributions
made by each individual nanobody residue are highly
homologous for 59H10, 48G11, and 37E7, diﬀering only in
the expected variant residues (D/Y56 and D/F 93, Figure S7a).
The corresponding scatter plot for the energetic contribution of
individual amino acids of p24 in Figure S7b, however, shows a
greater level of variation for the three complexes of p24 when it
is bound to 59H10, 48G11, or 37E7. For example, R162 of p24
in complex with 37E7, and D197 of p24 in complex with
48G11 both are signiﬁcantly unfavorable to binding, in contrast
to p24 in complex with 59H10, where R162 and D197 are
slightly unfavorable or neutral, respectively. E212 and E213 of
p24 in complex with 59H10 or 37E7, however, are both
favorable interactions in comparison to 48G11, for which the
interaction is slightly unfavorable. Notably, other interaction
diﬀerences do not deviate from one another by much more
than ±10 kJ/mol (approximately equivalent to a hydrogen
bond), whereas residues with diﬀerences greater than this, as
given in the above examples, are all charged amino acids. This
demonstrates small changes to the amino acid composition in
the three nanobodies has the consequence of disrupting the
overall electrostatics of binding with respect to the same
antigen with eﬀects on many of the residues. The crystal
structure in Figure 2 shows 59H10 bound to C-terminal helices
Figure 3. Examination of a measured crystal structure of nanobody D7
compared to calculated structures of 5910, 48G11, and 37E7 from
molecular dynamics simulations. (a) Crystal structure of PDB entry
2XA3, nanobody D7, which binds HIV gp120.40 The yellow circle
highlights the long CDR3 loop (in white), likely implicated in the
gp120 binding interaction. (b) The minimized structures of the
nanobodies reported here, with 37E7 and 48G11 superimposed onto
59H10, colored by amino acid sequence homology. (c) As in (b) but
colored by structural homology. For both homology models, the blue
indicates total conservation, red indicates no homology, and white is
moderate conservation. The highlighted CDR3 loop (yellow circle) is
much longer in the gp120-binding D7 as opposed to the p24-binding
nanobodies. Structures of (d) 59H10; (e) 48G11; (f) 37E7; shown in
rainbow coloring. The amino acid sites are shown as ball and stick
where they diﬀer from 59H10 and are highlighted in red circles. The
orange loop is the CDR3 indicated for comparison with D7. Structures
were equilibrated for 100 ns.
Figure 4. Analysis of molecular dynamics simulations to show the
binding interfaces of nanobodies and p24, colored red for favorable or
blue for unfavorable contribution to binding. (a) 59H10 and p24,
shown in two orientations. The salt bridge formed between 59H10
R50 and p24 E213, as observed in the crystal (Figure 2), persists
throughout the 40 ns dynamics as a highly energetically favorable
interaction. The unusual maturation mutation, W37, also contributes
favorably to the interface contacts; it forms a hydrogen bond and
makes hydrophobic contacts with p24. (b) As in (a) but in a diﬀerent
orientation. A second glutamate (p24 E212) also contributes favorably
to the binding. (c) 48G11 shown in the same orientation as 59H10 in
(a). The mutation F93D is drawn in van der Waals render and clearly
identiﬁes as unfavorable. (d) 37E7 shown in the same orientation as
59H10 in (b). The substitution D56Y appears to eliminate an
unfavorable charged interaction close to the 59H10-R50: p24 E213
salt bridge interaction, compare with the Y56 circled in yellow in (d).
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10 and 11; however, Figure S7b shows that the eﬀect of
nanobody binding is not limited to a conﬁned region of p24
and has a cascade eﬀect over the rest of the protein.
To probe the importance of hydrogen bonds in binding,
analysis of the 3 nanobodies each in complex with p24 was
performed to determine hydrogen bond occupancy. This can
change when the complex ﬂexes and moves over time and in
the presence of water molecules and salt ions. High occupancy
indicates the frequency with which the hydrogen bond persists
in the duration of the simulation as the thermodynamics of the
interprotein contacts are monitored. The histogram in Figure
5a shows the relative occupancy of each of the hydrogen bonds
for those suggested by the crystal structure (Figure 2) and
those between any of the three nanobodies and p24 that are
occupied for at least 11% of the molecular dynamics simulation.
The hydrogen bonding is deﬁned by a suitable donor and
acceptor atom being within a distance of 4 Å and angle of 30°
(as suggested by the crystal structure). Of note are the high
occupancy of the bonds between all nanobodies’ R50 to p24
E213 and the complete absence of the hydrogen bond between
48G11 W37 and p24 A204. For 59H10, the key interactions are
seen to be 59H10 R50 to p24 E213 (salt bridge, hydrogen
bond), 59H10 W37 to p24 A204 (hydrophobic interaction,
hydrogen bond), and 59H10 T98 to p24 D197 (hydrogen
bond; T98 is in the CDR3). 59H10 R50 to p24 E213 is a
persistent hydrogen bond and is also involved in formation of a
salt bridge (see Figures 2 and 4). For the 37E7−p24 complex,
fewer hydrogen bonds are formed by 37E7 R50 to p24 E213, as
p24 E213 also shares intraprotein hydrogen bonds with p24
T210, drawing it away from a close interaction with 37E7 R50).
A similar case is seen for 48G11 R50. The 48G11 W37 to p24
A204 hydrogen bond is abolished entirely by the nearby F93D
mutation (59H10 to 48G11) where the introduction of
hydrophilic D disturbs an otherwise hydrophobic patch. The
nanobody W37 to p24 A204 interaction is eliminated for
48G11, and the hydrogen bonding between 48G11 or 37E7
R50 and p24 E213 is less important. Note that p24 T210 shares
hydrogen bonds in these cases with p24 E213, with the eﬀect of
weakening the nanobody R50 to p24 E213. Also shown in
Figure 5a is p24 P207, which moves away from the hydrogen
bonds found with 59H10 R50 in the crystalline form when in
simulation in solution; hence, no occupancy is found.
The WXR motif (59H10 amino acids 36−38) is highly
conserved, with the central X amino acid most commonly F, R,
or a minority V. A sequence logo representing the relative
distribution of amino acids found at this site is shown in Figure
S8. An unusual “W” at position 37, giving WWR, was found in
only two other unique sequences out of almost 800 available
from the NCBI (GenBank AJ237346 and AF44291349,50). This
W37 was predicted both by analysis of the crystal structure and
from molecular dynamics simulations to positively contribute to
binding by formation of a hydrogen bond and to create an
alignment of hydrophobic patches on 59H10 and p24,
eliminated by F93D of 48G11.
The 59H10 R50 to p24 E213 interaction is clearly dominant
(present in every molecular dynamics “snapshot”) with an
occupancy of over 100% for all nanobodies. This is possible,
because there are multiple options for hydrogen bond pairs
formed between the arginine and glutamate (Figure 5b,c). A
maximum of four interactions is possible at an optimal
orientation of the amino acids, as observed in 59H10 but not
the others (see inset to Figure 5b), indicating this combination
of a strong electrostatic interaction from the salt bridge and
multiple hydrogen bonds at an advantageous positioning of
these amino acids results in a high aﬃnity nanobody−p24
interaction. Figure 5c also shows that, although the substitution
of D56Y (from 59H10 to 37E7) may appear to eliminate a
potentially repulsive charge at the site of the salt bridge, a more
Figure 5. (a) Histogram to compare the occupancy of hydrogen bonds
over the course of molecular dynamics simulations: black, 59H10; red,
48G11; green, 37E7. Examination of the occupancy of these bonds can
indicate the relative importance of each interaction in stabilizing the
complexes. Occupancy can reach over 100%, indicating more than one
hydrogen bond can form for the amino acid pair under consideration.
(b) Visualization of hydrogen bond occupancy from the results of the
molecular dynamics simulations using blue spheres on the atoms to
indicate occupancy over the duration of the simulation. Shown are (i)
59H10, (ii) 48G11, and (iii) 37E7. Inset: representation of the four
potential hydrogen bonds that can be formed between 59H10 R50 and
p24 E213. This enables a stronger interaction between the 59H10 R50
to p24 E213 salt bridge, with the possibility of up to four hydrogen
bonds forming at an optimal orientation. (c) Visualization of the
nanobody R50 to p24 E213 maximal position in (i) 59H10, versus the
suboptimal positioning in (ii) 48G11 and (iii) 37E7. Shown also are
the F55G and D56Y mutations (59H10 to 37E7) because of their
proximity to the salt bridge formed by nanobody R50 to p24 E213. It
could be that there is an important network of charges provided by the
F55−D56 that stabilizes this salt bridge further, perhaps a forming an
anion−π−anion interaction between 59H10 D56 and 59H10 F55 and
p24 E213.
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accurate determination of the charge distribution and polar-
ization eﬀects is required where the geometry of amino acids of
59H10 from the molecular dynamics appears to suggest a
favorable anion−π−anion interaction between 59H10 D56 and
59H10 F55 and p24 E213. This is not observed for 37E7.
To further probe the nature of the conjectured electrostatic
interactions between p24 and 59H10, electrostatic potential
energy maps of surfaces were calculated. Here, the Adaptive
Poisson-Boltzmann Solver was used to solve the Poisson-
Boltzmann equation, and the PDB2PQR interfaced with UCSF
Chimera using Assisted Model Building with Energy Reﬁne-
ment (AMBER) force ﬁelds for simulation of charge and
atomic radii was used.51,52 Potential isocontours are colored for
+1kT/e (blue) and −1kT/e (red) for all electrostatic potential
maps shown in Figure 6. The electrostatic potential surfaces
were calculated for all three nanobodies and found to show
large variations in charge distributions that result from the
single and triple amino acid substitutions. These are shown in
order of positivity 48G11 < 59H10 < 37E7 in Figure 6a−c,
respectively. Note that the changes in charge due to the
substitutions aﬀect the structures of the binding interface and
vice versa. That is, the structure aﬀects the distribution of
charges, so that the binding surface complementarity is altered
quite strikingly for these three nanobodies. The white skeleton
structures are shown below the electrostatic potential maps to
permit comparison of the binding interface of the three
nanobody structures. These simulations reveal the dramatic
eﬀects that can accrue from minor mutations, with one or three
amino acid changes out of 114 changing the spatial and
electrostatic environment of the binding site. The ease with
which single or multiple residues of these nanobodies can be
mutated, and hence alter their functional interfaces, makes
them particularly pliable as tools for nanoscale technology and
in the design of highly eﬃcient capture ligands for next
generation HIV tests. As shown in Figure 6b, 59H10 shows an
overall positively charged patch (circled in yellow) which
corresponds to the binding interface. This has electrostatic
complementarity to the binding interface of p24 (shown in
Figure 6d) which is an overall negatively charged patch (circled
in yellow). In comparison, 48G11 and 37E7 (Figure 6a,c,
respectively) do not have a perfectly positive electrostatic
region, demonstrating less compatibility with the electrostatic
potential of the p24. As shown, small changes in amino acids,
with large eﬀects on charge, seem to deﬁne the relative binding
behavior.
Given this electrostatic complementarity observed at the
binding interfaces of the 59H10 and p24, it was of interest to
compare subtypes of p24 that exhibit less strong binding.
Though 59H10 binds well to a breadth of subtypes, there were
exceptions found of some strains belonging to subtypes C (one
of seven tested) and D (two of four tested; Figures 1d and S1).
It has been reported that subtype D has been particularly hard
to detect in point of care tests on the ﬁeld.38 The electrostatic
potential of the p24 C-terminal domain binding interfaces of
strains that bound 59H10 variably are shown in Figure 6f−h.
Figure 6g,h shows disruption in the negative electrostatic
potential face at the p24 C-terminal binding site, indicating
electrostatic complementarity is an important contributor to
strong binding. These two exceptions to the strong binding by
59H10 to other strains of these subtypes (Figure 1d−f) support
the hypothesis that, if there is disruption to the homogeneity of
the negative electrostatic potential surface on the p24 binding
interface or if there is a disruption to the homogeneity of the
Figure 6. Electrostatic surface potentials of nanobodies and p24.
Potential isocontours are colored for +1kT/e (blue, positive) and
−1kT/e (red, negative). Electrostatic potentials and skeleton
structures of the binding interface for (a) 48G11, (b) 59H10, and
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positive electrostatic potential surface on the nanobody binding
interface, there appears to be diminished binding. Disrupting
the electrostatic complementarity at the p24 binding interface
appears to adversely aﬀect the binding kinetics, as demon-
strated in the functional data (Figure 1f). We can conjecture
that an overall electropositive map on the nanobody that
complements and an overall electronegative map on the C-
terminal of the p24 are preferable for strong aﬃnity binding.
To conclude, this paper reports the isolation of a novel
nanobody that binds to the earliest protein marker of HIV, p24,
with high aﬃnity, fast on-rates, and broad subtype speciﬁcity.
We report an X-ray crystal structure, which shows the binding
epitope and paratope regions on the p24 antigen 59H10
nanobody, respectively. Igonet et al.53 previously reported a
nanobody that binds a diﬀerent epitope region on p24 (PDB
code 2XV6); however, the epitope reported and examined here
would be accessible in many oligomeric forms of the p24
antigen. This is very advantageous and has particularly exciting
repercussions in the design of a diagnostic or therapeutic tool.
We have brought together functional experimental data, a
crystal structure, and molecular dynamics simulations to
elucidate the structural basis of this novel, high aﬃnity
nanobody. Further, the atomistic detail from the crystal
structure of 59H10 provides a template with which to compare
nanobodies with diﬀering aﬃnities using molecular dynamics
simulations. The apparently simple mutation of a single amino
acid within the CDR3 loop causes a cascade eﬀect on
electrostatic charge distribution across the faca̧de of the
nanobody, with a massive impact on binding aﬃnity. Indeed,
the small size of these nanobodies, together with the
concomitant facility with which their single chain structure
can be manufactured and modeled, means that structure−
function study ﬁndings can be fed back to iteratively improve
the design for speciﬁc functions. Simulations shown here
highlight the importance of the salt bridge of 59H10 R50 to
p24 E213, the hydrogen bond of 59H10 W37 to p24 A204 and
the alignment of hydrophobic patches, and the hydrogen bond
59H10 CDR3 T98 to p24 D197 and electrostatic comple-
mentary regions for high aﬃnity binding. This information is
valuable with respect to the design and development of tools
that exploit the 59H10−p24 interaction. There is much scope
for applications of this new understanding. The rapid on-rates
and strong binding constants of 59H10 are advantageous in
diagnostic assay formats, resulting in a fast time for results and
high sensitivity, which is particularly important in the context of
POC tests used in a primary healthcare setting. Moreover,
eﬀective anti-HIV tools for use in diagnostics, prevention of
transmission, and therapy need to be able to bind to the wide
array of global HIV-1 subtypes with high aﬃnity, and 59H10
fulﬁls these criteria. The development of biheads, formed from
two 59H10 nanobodies joined by a ﬂexible linker, could further
enhance sensitivity via multimeric complex formation with
engineered tags to orient nanobodies for all sensing
applications.22,54 Once the interaction is understood, mod-
iﬁcations to aﬀect parameters such as, for example, binding
aﬃnity or attachment site to a surface, can be manipulated to
create biological sensors of maximum sensitivity.
To close, we speculate that the potential of nanobodies goes
beyond replacing traditional antibodies in conventional
laboratory assays and could lead to entirely new classes of
biosensor technologies based on advanced nano and quantum
mechanical tools. These include ultrasensitive plasmonic
ELISAs and quantum dot FRET assays which directly beneﬁt
from smaller nanobody capture coatings and reduced donor−
acceptor distance to innovative nanoswitches triggered by the
eﬀect of nanobody−p24 complex formation.
■ METHODS
Nanobody Generation. The library was produced from
inoculation of two lama glama, and nanobodies were selected
and produced in E. coli as described previously,29,55 using
recombinant p24 immunogens (ARP678, ARP695, and
EVA620) from the AIDS Regent Program (NIBSC, Potters
Bar, UK).
Mutagenesis. For mutagenesis of 59H10 vector, oligonu-
cleotides EG185 (GCCGTCTATTACTGTGATGCAG-
CCCTTGACACCGCCTACTGG) and EG186 (CCAGTAG-
GCGGTGTCAAGGGCTGCATCACAGTAATAGACGGC)
were ampliﬁed with PCR using the following program and Pfu
Turbo (Stratagene): 95 °C for 2 min; 18 cycles of 95 °C for 30
s, 55 °C for 1 min, and 68 °C for 4 min; 68 °C for 5 min.
Samples were digested with DpnI to remove template DNA,
concentrated by NaAc/EtOH precipitation, and used to
transform E. coli HB101 (Promega). Clones were conﬁrmed
by sequencing. Vector was retransformed into TG1 (Lucigen)
prior to expression.
Recombinant p24 Protein. The following were used in
the study: AG6054 (B; BH10 Aalto BioReagents, Ireland),
EVA620 (B; LAI, NIBSC), ARP0695 (C; consensus NIBSC),
HIV 1033 (CRF01_AE, CM240, ImmunoDX, USA), and
Subtypes D, N, and O (NDK, 06CM-U14296, BCF06;
SinoBiological).
Puriﬁed p24 Protein. The bacterial expression plasmid
pET11a, containing the HIV-1 capsid coding sequence, was
obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: pWISP98-85 from Dr. Wes Sundquist.
The recombinant HIV-1 capsid protein p24 was puriﬁed as
described previously.56 Puriﬁed p24 was complexed with the
nanobody 59H10, and the complex was further puriﬁed by size
exclusion chromatography on a Superdex 75 10/300 GL in a
buﬀer containing 25 mM Hepes, pH 7.5, 150 mM NaCl.
Enzyme-Linked Immunosorbent Assay (ELISA). ELISA
was used in both indirect and sandwich format to assay for
activity. For indirect ELISAs, recombinant p24 was bound to
MaxiSorp 96-well plates (Nunc) between 16 and 1000 ng/mL
in 50 mM sodium carbonate buﬀer pH 9.6 at 4 °C overnight.
The following morning, plates were washed and blocked in 2%
Figure 6. continued
(c) 37E7 are shown in order of overall positivity (37E7 has the highest
total positive charge). Note the changes in amino acids at CDR2 and
CDR3 create an electronegativity gradient over the entirety of the
nanobodies from 48G11 (least electropositive), through 59H10 to
37E7 (most electropositive). Circled in yellow is the binding interface
in 59H10 (b). (d) Electrostatic potentials and skeleton structures of
full p24 (subtype B, based on PDB code 1E6J). The region circled in
yellow highlights the binding interface for 59H10. The skeleton
structure of p24 is shown below for comparison. (e) Electrostatic
potentials of full p24 and skeleton structure of 59H10, showing 59H10
binding to p24. There is charge complementarity upon complex
formation between the positive (blue region on the 59H10) and the
negative (red region on the p24). (f) The electrostatic potential of the
p24 binding site for 59H10 is shown for speciﬁc isolates of diﬀerent
subtypes of p24; (i) subtype B (as mentioned previously, for
comparison), (ii) subtype C, ARP695, and (ii) subtype D, isolate
DEMD10CM009.
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BSA or nonfat milk in PBS-0.05% Tween for 2 h. Nanobody or
mAb (NIH-3537, AIDS Reagent Program; CP-HIV-1/2,
Capricorn Products) was added in blocking buﬀer for 2 h.
After binding of primary antibody, plates were washed 4× in
PBS-T; then, secondary antibody was bound (goat antimouse-
HRP, Dako; antimyc-HRP, Roche; streptavidin−HRP, Sigma)
for 1−2 h. Plates were washed 4−6× in PBS-T; peroxidase
activity was assayed with 1× TMB (eBioscience), and 5−15
min later, 0.2 M H2SO4 was added. The OD was read at 450
nm (SpectraMax, Molecular Devices). For sandwich ELISAs,
assays were carried out essentially as above except capture
antibodies were used to coat plates overnight at 78−313 ng/
mL, and antigen was bound for 1.5 h at 37 °C.
Crystallization, Data Collection, and Structure Deter-
mination. Crystal screening was performed at the High
Throughput Crystallization Laboratory (HTX lab, Grenoble) in
96-well sitting drop vapor diﬀusion plates (Greiner). Following
optimization, crystals used for diﬀraction studies were grown at
20 °C in hanging drop vapor diﬀusion plates and obtained by
streak seeding.
The p24−59H10 complex was crystallized in 100 mM Tris
base, pH 8.0, 20%, and polyethylene glycol (PEG) 6000 by
mixing 1 μL of the reservoir and 1 μL of protein at a
concentration of 8 mg/mL. The crystals were cryoprotected in
the crystallization buﬀer containing 25% ethylene glycol and
ﬂash cooled in liquid N2 before data collection. Data were
collected on beamline ID30-B at the ESRF at a wavelength of
0.976251 Å. Data were processed with the program XDS.57 The
crystals belong to space group P1211 (Table 3).
The structure was solved by molecular replacement using the
program Phaser58 using the PDB 2GOL (for p24) and 4LDO
(for the nanobody 59H10) as input models. The model was
rebuilt using COOT59 and reﬁned using REFMAC60 and
Phenix.61 Statistics for data reduction and structure reﬁnement
are presented in Table 3. The models were evaluated by using
COOT and Phenix validation tools. Two copies of the p24−
59H10 complex are present in the asymmetric unit. Only the
C-terminal domain of p24 is present in the crystal and chains A
and C contain residues 149 to 221. For the nanobody 59H10
and chains B and D, residues are numbered according to Kabat.
The structure was reﬁned against 2.76 Å data to an R/Rfree of
22.11/25.35%. 98.64/1.36% of the residues are within the most
favored and allowed regions of a Ramachandran plot. Molecular
graphics ﬁgures were generated with PyMOL (W. Delano; The
PyMOL Molecular Graphics System, Version 1.8 Schrödinger,
LLC, http://www.pymol.org).
Molecular Dynamics Simulations. All atomistic classical
molecular dynamics (MD) simulations were performed using
NAMD62 and GROMACS packages63 and visualized using
VMD64 and Chimera.51 Initial MD runs took models for the
48G11, 59H10, and 37E7 obtained from Swissprot. These
structures were minimized, using the NAMD conjugate
gradient and line search algorithm; relaxed geometry results
are as shown in Figure 3b,c. Subsequently, these structures were
prepared for a 100 ns NVT (canonical; constant volume,
constant temperature) ensemble with Langevin dynamics in an
explicit water sphere just covering the protein with no periodic
boundary conditions. The TIP3P potential was used for the
water interactions. Force ﬁelds par_all27_prot_lipid_na and
top_all27_prot_lipid_na.inp were used for the nanobodies.
The simulations were run at 333 K, with a Langevin damping
coeﬃcient of 1 ps−1, in order to accelerate any possible
observation of protein unfolding and probe conformational
space. The ﬁnal equilibrated structures from this run were used
as input for production stage runs; see Figure 3d−f for skeleton
models of the resulting conformations. These were put into
cubic water boxes with 10 Å between the box boundary and the
edge of the protein. The production runs maintained a constant
pressure of 1 atm at 310 K, NPT (isothermal−isobaric)
ensemble, and pH 7 (approximately physiological pH) where
the disulﬁde bridge is intact. Full system periodic electrostatics
were calculated using Particle Mesh Ewald (PME) grids with
counterions added for charge neutrality. A cutoﬀ of 12 Å was
used for the Lennard-Jones force ﬁeld parameters; the SHAKE
algorithm was used to constrain all hydrogen-containing bonds,
and the time step was 2 fs, as in the equilibration step.
The MD simulations described above demonstrated the
stability of the three nanobodies based on models. The
experimental crystal structure of 59H10 bound to p24 also
provided atomistic coordinates for the complex. This (PDB
5O2U) was then used as input for molecular dynamics
(GROMACS) calculations to assess binding,63 with 48G11
and 37E7 superimposed onto the binding site for 59H10. For
these binding comparisons, coordinate and topology ﬁles were
parametrized using the AMBER99SB force ﬁeld, with TIP3P
water molecules added to solvate, surrounding the protein
complex in the center of a dodecahedron periodic box with a
side of at least 10 Å between the edge of the box and the
protein. Hydrogen atoms were added to imitate protonation
states at pH 7 and with a disulﬁde bridge accounted for in the
nanobody and in the p24. In each case, the system was
neutralized and 75 mM of NaCl was added to match the X-ray
conditions, and again, full system periodic electrostatics were
calculated using Particle Mesh Ewald (PME). The minimiza-
tion was performed using the steepest descent algorithm, and
then, an equilibration was run using an NVT ensemble to heat
to 310 K using a modiﬁed Berendsen thermostat; then, an NPT
was run with Parrinello−Rahman coupling for pressure control
at 1 atm. Production runs were then completed for 40 ns total
using a 2 fs time step, requiring 20 million steps of integration.
All bonds were constrained with the parallel LINCS method,
with short-range nonbonded electrostatic interactions calcu-
lated with a cutoﬀ of 9 Å and van der Waals with a cutoﬀ of 1.4
Å. This method follows the protocol outlined as in
“g_mmpbsa”, a GROMACS tool to calculate Molecular
Mechanics Poission-Boltzmann Surface Area (MMPBSA) of
binding interaction energies.65 Input into g_mmpbsa was then
generated from the MD results: 400 frames every 0.1 ns was
used to represent uncorrelated snapshots from the 40 ns
duration. Energies from the molecular mechanics were
calculated using the Lennard-Jones and Coulomb potential.
Polar energies were calculated at an ionic strength of NaCl 75
mM, with the protein and solvent dielectric constants of 2 and
80, respectively. As these systems are charged (with subtype B
p24 at −4 electrons), the nonlinear Poisson-Boltzmann
equation was solved using APBS. The apolar energies were
calculated on the basis of a ﬁtting to the surface tension for the
solvent accessible surface area. Results of these simulations are
displayed in Figures 4, 5 (MD), S6 (MD), and S7 (MMPBSA)
and Table S2 (MMPBSA).
Biolayer Interferometry. A binding comparison of the
nanobodies and mAbs (termed analytes) to immobilized p24
subtype B (AG6054) was performed on an Octet RED96
(ForteB́io, UK). AG6054 was immobilized on amine-reactive
probes (AR2G Biosensor, ForteB́io). The probes were activated
by a 5 min incubation in a freshly mixed sulfo-NHS-EDC
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solution (10 mM/20 mM), before incubation for 10 min in a
20 μg/mL solution of AG6054 in 10 mM acetate buﬀer (pH5)
and then 5 min in a 1 M solution of ethanolamine−HCl (pH
8.5), washed in the kinetics buﬀer provided, and then dipped in
the sample diluted in kinetics buﬀer. Each run consisted of
testing seven diﬀerent concentrations of analyte once. Analyte
binding proceeded for at least 60 min. Normalization was
carried out using an in situ probe functionalized with p24 and
dipped in sample solution without added analyte, to account for
nonspeciﬁc reactions occurring on the surface. At high
concentrations of analyte, the signal appears to plateau and
reach equilibrium within the time frame of the experiment.
However, at low analyte concentrations, the signal does not
reach equilibrium within this time frame. Therefore, the
equilibrium signal was determined by ﬁtting the raw data for
each concentration to the exponential equation: y = A[1 −
exp(−kobst)], where y is the binding in nm, A represents the
equilibrium signal, kobs is the observed rate constant, and t is
time. The equilibrium signal (A) as a function of the
concentration was then ﬁtted to a Langmuir isotherm y =
B[c/KD + c], where KD represents the binding aﬃnity of the
protein to p24, B is the saturation signal when all the available
sites are occupied, and c is analyte concentration. The analyses
in Figure 1f−h were obtained by normalizing the raw data by
the saturation signal B, following the method reported by
Martin and co-workers.66,67 Figure 1g is a log/linear plot of the
fractional saturation (ratio A/B) as a function of the
concentration, for each analyte. A detailed description of the
analysis is provided in Figure S3. The kinetic on-rate constant
kon and oﬀ-rate constant koff presented in Table 1 are deﬁned by
the equation kobs = koff + kon × c and were determined as the
slope and intercept, respectively, of the linear regression
performed on kobs as a function of the concentration (example
shown for 59H10 and CP-HIV-1/2 in Figure S3). All data in
Table 1 are presented with the corresponding 95% conﬁdence
intervals.
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